Every 10-Q that Quoin Pharmaceuticals, Ltd. American (QNRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QNRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNRX filings page.
Quoin Pharmaceuticals Ltd. is a late-stage clinical specialty pharma company focused on rare dermatologic diseases. Its lead candidate, QRX003, is in pivotal registrational development for Netherton Syndrome, with U.S. and European clinical sites open and eight pediatric patients treated under a compassionate use program.
Regulatory progress includes Japan Orphan Drug Designation for QRX003 in Netherton Syndrome, FDA Fast Track Designation, conditional FDA brand-name approval (QYLEKI), and FDA clearance of an IND to start a Phase 2 study of QRX003 in Peeling Skin Syndrome. The QRX009 topical rapamycin program is advancing via multiple investigator-led studies.
For the quarter ended June 30, 2026, Quoin recorded a net loss of $5.37 million (six‑month loss $10.37 million). Total assets were $12.0 million, including $3.85 million in cash and equivalents and $6.95 million in investments; shareholders’ equity was $3.93 million and the accumulated deficit reached $81.3 million. Management discloses substantial doubt about continuing as a going concern without additional financing.
Quoin Pharmaceuticals Ltd. reported a larger quarterly loss as it advances late-stage programs for rare skin diseases and faces a going concern warning. For the three months ended March 31, 2026, net loss widened to $4.99 million from $3.81 million a year earlier.
Research and development spending rose to $3.43 million, driven mainly by QRX003 clinical studies and early work on QRX009. General and administrative expenses were $1.70 million. Quoin ended the quarter with $3.12 million in cash and $10.92 million in U.S. Treasury investments, and an accumulated deficit of about $76.0 million.
Management concluded there is substantial doubt about the company’s ability to continue as a going concern for at least one year without new funding. The company continues pivotal preparations for QRX003 in Netherton Syndrome and development of QRX009, while holding nine commercial license and supply agreements that have not yet generated revenue.
Quoin Pharmaceuticals (QNRX) reported Q3 2025 results with a net loss of $3.95 million as operating expenses rose to $4.02 million. Research and development climbed to $2.28 million (up ~111%) as the company advanced two pivotal QRX003 studies in Netherton Syndrome. As of September 30, cash and cash equivalents were $1.83 million and investments were $3.58 million.
Subsequent events strengthened liquidity: on October 10, Quoin closed a private placement for gross proceeds of approximately $16.6 million (about $15 million net) and later received $3.3 million from exercises of December 2024 warrants. Management concluded available resources are sufficient for at least one year after issuance of the financial statements. The FDA granted Orphan Drug Designation to QRX003 on October 21, 2025. Quoin previously regained Nasdaq minimum bid compliance in April 2025 following an ADS ratio change and reverse split.